首页> Nature communications> Epigenetic activation of the FLT3 gene by ZNF384 fusion confers a therapeutic susceptibility in acute lymphoblastic leukemia.

Epigenetic activation of the FLT3 gene by ZNF384 fusion confers a therapeutic susceptibility in acute lymphoblastic leukemia.

导出 OA

翻译打印收藏纠错

第一作者： Xujie,Zhao

第一单位： Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN, USA.

作者： Xujie,Zhao ^[1] ; Ping,Wang ^[2] ; Jonathan D,Diedrich ^[1] ; Brandon,Smart ^[1] ; Noemi,Reyes ^[1] ; Satoshi,Yoshimura ^[1] ; Jingliao,Zhang ^[1] ; Wentao,Yang ^[1] ; Kelly,Barnett ^[1] ; Beisi,Xu ^[3] ; Zhenhua,Li ^[1] ; Xin,Huang ^[4] ; Jiyang,Yu ^[4] ; Kristine,Crews ^[1] ; Allen Eng Juh,Yeoh ^[5] ; Marina,Konopleva ^[6] ; Chia-Lin,Wei ^[2] ; Ching-Hon,Pui ^[7] ; Daniel,Savic ^[1] ; Jun J,Yang ^[8]

作者单位： Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN, USA. ^[1] The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA. ^[2] Center for Applied Bioinformatics, St. Jude Children's Research Hospital, Memphis, TN, USA. ^[3] Department of Computational Biology, St. Jude Children's Research Hospital, Memphis, TN, USA. ^[4] Department of Pediatrics, National University of Singapore, Singapore, Singapore. ^[5] Departments of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. ^[6] Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA. ^[7] Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN, USA. jun.yang@stjude.org.;Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA. jun.yang@stjude.org. ^[8]